Journal
MOLECULAR THERAPY
Volume 22, Issue 7, Pages 1310-1319Publisher
CELL PRESS
DOI: 10.1038/mt.2014.27
Keywords
-
Categories
Funding
- CDMRP Department of Defense Breast Cancer Research Program (DOD/BCRP) [W81XWH-09-1-0212]
- National Center for Research Resources NIH [UL1TR000371]
- University of Texas MD Anderson Cancer Center [P30 CA016672]
- DOD/BCRP [W81XWH-11-1-0103]
- Susan G. Komen Breast Cancer Foundation [KG101394]
Ask authors/readers for more resources
Ongoing clinical trials target the aberrant PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in breast cancer through administration of rapamycin, an allosteric mTOR inhibitor, in combination with paclitaxel. However, synergy may not be fully exploited clinically because of distinct pharmacokinetic parameters of drugs. This study explores the synergistic potential of site-specific, colocalized delivery of rapamycin and paclitaxel through nanoparticle incorporation. Nanoparticle drug loading was accurately controlled, and synergistic drug ratios established in vitro. Precise drug ratios were maintained in tumors 48 hours after nanoparticle administration to mice, at levels twofold greater than liver and spleen, yielding superior antitumor activity compared to controls. Simultaneous and preferential in vivo delivery of rapamycin and paclitaxel to tumors yielded mechanistic insights into synergy involving suppression of feedback loop Akt phosphorylation and its downstream targets. Findings demonstrate that a same time, same place, and specific amount approach to combination chemotherapy by means of nanoparticle delivery has the potential to successfully translate in vitro synergistic findings in vivo. Predictive in vitro models can be used to determine optimum drug ratios for antitumor efficacy, while nanoparticle delivery of combination chemotherapies in preclinical animal models may lead to enhanced understanding of mechanisms of synergy, ultimately opening several avenues for personalized therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available